Fibrinogen Thrombin Assay
Fibrinogen Thrombin Assay - Related Videos
08:01
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
0 Views •
2026
This protocol describes the Nijmegen Hemostasis Assay, which enables simultaneous, time-resolved measurement of thrombin and plasmin generation to provide an integrated assessment of coagulation and fibrinolysis. The assay aims to improve characterization of hemostatic balance in research and clinical settings beyond the scope of conventional hemostatic tests.
18:30
RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells
0 Views •
Cited by 12 •
2013
This protocol presents a complete and detailed procedure to apply RNA-seq, a powerful next-generation DNA sequencing technology, to profile transcriptomes in human pulmonary microvascular endothelial cells with or without thrombin treatment. This protocol is generalizable to various cells or tissues affected by different reagents or disease states.
14:14
Optimized Fibrin Gel Bead Assay for the Study of Angiogenesis
0 Views •
Cited by 166 •
2007
This video demonstrates the protocol of an in vitro angiogenesis assay that recapitulates several stages of angiogenesis. Time-lapse images of sprouting, lumen formation, branching and anastomosis - key features of angiogenesis - are shown.
09:23
Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation
0 Views •
Cited by 4 •
2016
Cancer cells are embedded in a collagen gel and then sandwiched in an acellular fibrin gel to generate a 3D culture system in which the invasiveness and formation of satellite tumors may be monitored.
04:08
Bead Sprouting Assay for Early-Stage Angiogenesis Assessment: An In Vitro Bead-Based Model to Study Endothelial Sprouting in the Presence of Pericytes
0 Views •
2025
This video demonstrates a modified microcarrier beads-based assay incorporating pericytes to study endothelial sprouting during the early stages of angiogenesis. The assay provides an in vitro experimental model to understand molecular mechanisms of angiogenesis and the effect of anti-angiogenetic therapeutics.
FAQs
The method first dilutes the plasma and then adds a high concentration of thrombin. This rapidly drives fibrinogen conversion to fibrin, producing a measurable clotting time. The laboratory compares that time with a calibration curve prepared for the assay, allowing the observed clot formation result to be translated into an estimated fibrinogen concentration.
High thrombin places the conversion of fibrinogen to fibrin at the center of the measurement. Under the Clauss-based approach, the resulting clotting time is used with the calibration curve to estimate fibrinogen. This design supports assessment of the protein’s functional contribution to clot formation rather than relying only on its presence in plasma.
Concentration describes how much fibrinogen is present, whereas functional activity reflects its ability to participate in clot formation. The assay can support evaluation of either aspect, depending on how the result is interpreted. This distinction is important for recognizing inherited fibrinogen abnormalities, where the amount of protein and its clot-forming performance may not correspond.
The calibration curve provides the relationship between measured clotting times and fibrinogen levels. After plasma is exposed to thrombin and a clot forms, the observed time is matched to this relationship to estimate the sample’s result. Without that comparison, clot formation time would not directly provide a fibrinogen concentration.
A typical workflow uses plasma, dilutes the specimen, exposes it to a high concentration of thrombin, and records the time until clot formation. The measured time is then compared with a calibration curve to estimate fibrinogen. These steps connect the biochemical conversion of fibrinogen to fibrin with a quantitative laboratory result.
The test can help evaluate changes in coagulation status during clinical care and investigate conditions associated with abnormal clotting or bleeding. The overview specifically identifies disseminated intravascular coagulation, liver disease, and inherited fibrinogen abnormalities as relevant contexts. Results therefore contribute to assessment of whether fibrinogen-related clot formation may be impaired or altered.
By assessing fibrinogen concentration or functional activity, the assay can contribute to investigation of bleeding disorders and thrombotic disorders. It is also relevant when disseminated intravascular coagulation, liver disease, or inherited fibrinogen abnormalities are being considered. The result provides focused information about a plasma protein that is essential for forming blood clots.
The assay links a defined biochemical reaction, thrombin-mediated conversion of fibrinogen into fibrin, to an observable clotting endpoint. Comparing that endpoint with a calibration curve produces an estimate of fibrinogen levels or activity. In biochemical research, this supports study of coagulation status and changes involving fibrinogen-dependent clot formation.